Chordate Medical Holding AB Logo

Chordate Medical Holding AB

Develops a patented, drug-free neuromodulation treatment for migraine and rhinitis.

CMH | ST

Overview

Corporate Details

ISIN(s):
SE0021486131 (+1 more)
LEI:
549300R0GG2J3S0BFN79
Country:
Sweden
Address:
C/O Regus, 164 40 Kista

Description

Chordate Medical Holding AB is a medical technology company that has developed and patented Ozilia®, a CE-marked, drug-free neuromodulation treatment. The technology is indicated for the treatment of chronic migraine and chronic rhinitis. Ozilia® provides a non-pharmacological alternative to conventional medications, such as pills or injections, and is associated with minimal side effects. The company's business model is centered on building value through an extensive patent portfolio, clinical studies demonstrating efficacy, and establishing commercial success in selected markets with the goal of a future exit.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chordate Medical Holding AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chordate Medical Holding AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chordate Medical Holding AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-14 Tommy Hedberg Other Other 2,917 11,668.00 SEK
2024-03-26 Anders Weilandt Other Buy 800,000 41,440.00 SEK
2024-03-26 Anders Weilandt Other Buy 200,000 10,540.00 SEK
2023-05-26 Anders Weilandt Other Buy 2,000,000 84,000.00 SEK
2023-05-26 Jan Hermansson Other Buy 750,000 31,500.00 SEK
2023-05-26 Nils Henrik Milton Rammer Other Other 350,000 14,700.00 SEK
2023-05-26 Caroline Brandberg Other Other 225,000 9,450.00 SEK
2023-05-26 Tommy Hedberg Other Buy 225,000 9,450.00 SEK
2023-01-09 Anders Weilandt Other Buy 3 2.10 SEK
2022-02-25 Anders Weilandt Other Buy 51,292 3,949,484.00 SEK

Peer Companies

OncoTherapy Science, Inc. Logo
Biopharmaceutical company researching and developing novel anti-cancer therapies.
Japan
4564
Optipharm.CO.,LTD Logo
Develops animal health solutions, biotherapeutics, and xenotransplantation technology.
South Korea
153710
ORAGENICS INC Logo
Biotechnology company developing intranasal therapeutics for neurological disorders.
United States of America
OGEN
Develops organoid-based technologies for drug development and regenerative medicine.
South Korea
476040
Orum Therapeutics, Inc. Logo
Clinical-stage biotech developing degrader-antibody conjugates to treat cancer.
South Korea
475830
OSR Holdings, Inc. Logo
A healthcare holding company acquiring and developing innovative therapies and solutions.
United States of America
OSRH
OS Therapies Inc Logo
Clinical-stage immunotherapy company developing treatments for HER2-positive cancers.
United States of America
OSTX
OXFORD BIODYNAMICS PLC Logo
Develops and commercializes precision medicine tests for oncology using 3D genomics.
United Kingdom
OBD
Oxurion NV Logo
Acquires majority stakes in European pharmaceutical subcontractors.
Belgium
OXUR
Pasithea Therapeutics Corp. Logo
Develops treatments for central nervous system disorders, RASopathies, and solid tumors.
United States of America
KTTA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.